A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

Trial Profile

A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Vobarilizumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms STEADY
  • Sponsors Ablynx
  • Most Recent Events

    • 23 Feb 2017 Status changed from recruiting to active, no longer recruiting, according to an Ablynx media release.
    • 06 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 04 Aug 2015 Ablynx administered the first dose in this study, according to a company media release. Results are expected in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top